Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2010

Biovail and MedGenesis Receive $2.1M Grant for Parkinson Disease Trials

  • Biovail and MedGenesis Therapeutix confirmed the receipt of $2.1 million from the Michael J. Fox Foundation to fund further clinical development of glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson disease.

    GDNF is a naturally occurring growth factor that protects and promotes the survival of dopamine-producing nerve cells, the firms explain. The candidate is being developed by Biovail and MedGenesis through a collaboration agreement announced in January. Parkinson disease is the first GDNF indication the partnership is focused on.

    The GDNF co-development agreement followed on from MedGenesis’ negotiation of an exclusive, worldwide license to the GDNF protein from Amgen for both CNS and non-CNS applications. This deal, also announced in January, gave Amgen a small equity stake in MedGenesis.

    .   



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »